KUALA LUMPUR, Nov 11 (Bernama) -- AGC Biologics, a contract biopharmaceutical manufacturer, has partnered with Child’s Cure Genetic Research, a foundation set up by parents of children with CDKL5 deficiency disorder, to explore a messenger RNA (mRNA) therapy for the rare genetic brain disorder.
AGC Biologics Explores mRNA Therapy For Rare Brain Disorder
AGC Biologics Explores mRNA Therapy For Rare Brain
BE Bernama 
Key takeaways
AGC Biologics partners with Child’s Cure to explore mRNA therapy for CDKL5 deficiency disorder.
- AGC Biologics collaborates with Child’s Cure to develop mRNA therapy for a rare brain disorder.
- The therapy aims to reduce seizures and improve neurological development in patients.
- AGC Biologics plans to offer mRNA development and production in Yokohama from 2027.
Summarised automatically by AI from the original article by Bernama. AI can make mistakes, so check the original for details.
Read the full story on Bernama That's the opening of the story. The full piece is published by Bernama.
Continue reading ↗ Story details
- Published
- Section
- news
- Format
- Article
- Original
- bernama.com ↗
Topics
